[
    [
        {
            "time": "",
            "original_text": "天坛生物: q4收入正常, 血制品继续稳健增长",
            "features": {
                "keywords": [
                    "天坛生物",
                    "Q4",
                    "收入",
                    "血制品",
                    "稳健增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天坛生物: q4收入正常, 血制品继续稳健增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "13家公司新闻现重大利空",
            "features": {
                "keywords": [
                    "13家公司",
                    "新闻",
                    "重大利空"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "13家公司新闻现重大利空",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【医药-马帅】天坛生物业绩预告点评：Q4费用确认比较多，调浆获批产能利用率提升",
            "features": {
                "keywords": [
                    "医药",
                    "天坛生物",
                    "业绩预告",
                    "Q4",
                    "费用确认",
                    "调浆获批",
                    "产能利用率",
                    "提升"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药-马帅】天坛生物业绩预告点评：Q4费用确认比较多，调浆获批产能利用率提升",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]